References
- Jones RN, MYSTIC Advisory Board. Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. J Antimicrob Chemother 2000; 46 (Topic T2):1-8.
- Swartz MN. Hospital-acquired infections: Diseases with increasingly limited therapies. Proc Natl Acad Sci USA 1994; 91: 2420–2427.
- Gniadkowski M. Evolution and epidemiology of extend-ed-spectrum I3-lactamases (ESBLs) and ESBL-producing microorganisms. Clin Microbiol Infect 2001; 7: 597–608.
- Paterson DL, Ko WC, Von Gottberg A, et al. Outcome of cephalosporin treatment for serious infections due to appar-ently susceptible organisms producing extended-spectrum 13-lactamases: Implications for the clinical microbiology laborato-ry. J Clin Microbiol 2001; 39: 2206-2212.
- Pitout JDD, Thomson KS, Hanson ND, Ehrhardt AF, Moland ES, Sanders CC. Beta-lactamases responsible for resistance to expanded-spectrum cephalosporins in Klebsiella pneumoniae, Escherichia coli, and Proteus mirabilis isolates recovered in South Africa. Antimicrob Agents Chemother 1998; 42: 1350–1354.
- Goossens H for the MYSTIC Study Group (European centers only). MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) results from Europe: Comparison of antibiotic susceptibilities between countries and centre types. J Antimicrob Chemother 2000; 46 (Topic T2): 39-52.
- Bonnet R, De Champs C, Sirot D, Chanal C, Labia R, Sirot J. Diversity of TEM mutants in Proteus mirabilis. Antimicrob Agents Chemother 1999; 43: 2671–2677.
- Coudron PE, Moland E, Thomson KS. Occurrence and detection of AmpC beta-lactamases among Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis isolates at a veterans medical center. J Clin Microbiol 2000; 38: 1791–1796.
- Luzzaro F, PeriIli M, Amicosante GL, et al. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor com-binations. Int J Antimicrob Agents 2001; 17: 131–135.
- Mariotte S, Nordmann P, Nicolas MH. Extended-spectrum I3-lactamase in Proteus mirabilis. J Antimicrob Chemother 1994; 33: 925–935.
- Perilli M, Segatore B, de Massis MR, et al. TEM-72, a new extended-spectrum beta-lactamase detected in Proteus mirabilis and Morganella morganii in Italy. Antimicrob Agents Chemother 2000; 44: 2537–2539.
- Watanabe Y, Yokota T, Higashi Y, Wakai Y, Mine Y. In vitro and in vivo transferable beta-lactam resistance due to a new plasmid-mediated oxyminocephalosporinase from a clini-cal isolate of Proteus mirabilis. Microbiol Immunol 1991; 35: 87–97.
- Chanal C, Bonnet R, De Champs C, Sirot D, Labia R, Sirot J. Prevalence of beta-lactamases among 1,072 clinical strains of Proteus mirabilis: A 2-year survey in a French hos-pital. Antimicrob Agents Chemother 2000; 44: 1930–1935.
- De Champs C, Bonnet R, Sirot D, Chanal C, Sirot J. Clinical relevance of Proteus mirabilis in hospital patients: A two year survey. J Antimicrob Chemother 2000; 45: 537.
- Turner PJ. MYSTIC (Meropenem Yearly Susceptibility Test Information Collection): A global overview. J Antimicrob Chemother 2000; 46 (Topic T2): 9-23.
- Turner PJ, Greenhalgh JM, Edwards JR, McKellar J. The MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) programme. Int J Antimicrob Agents 1999; 13: 117–125.
- Pfaller MA, Jones RN. A review of the in vitro activity of meropenem and comparative antimicrobial agents tested against 30,254 aerobic and anaerobic pathogens isolated worldwide. Diagn Microbiol Infect Dis 1997; 28: 157–163.
- Jones RN. A review of the in vitro spectrum of imipen-em. Am J Med 1985; 78 (Suppl 6A): 22-32.
- Jones RN, Aldridge KE, Allen SD, et al. A multicenter in vitro evaluation of SM-7338: A new carbapenem. Antimicrob Agents Chemother 1989; 33: 562–565.
- National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial tests for bacteria that grows aerobically. Approved standard M7-A5. Wayne, PA: NCCLS, 2000.
- National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Supplemental tables, M100-512. Wayne, PA: NCCLS, 2002.